Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Prostatic Neoplasms 3Multiple Myeloma 2Lymphatic Metastasis 1Bone Metastases 1

Interventions

Dexamethasone 132Lenalidomide 58Bortezomib 56Calcium Dobesilate 44Melphalan 41carfilzomib 38pomalidomide 36Cyclophosphamide 35daratumumab 23belantamab mafodotin 21Peripheral Blood Stem Cell Transplantation 17ixazomib 16dexamethasone acetate 13Filgrastim 13Bendamustine Hydrochloride 13fludarabine phosphate 12fludarabine 12dexamethasone 21-phosphate 12Tacrolimus 12auricularum 11Whole-Body Irradiation 11liposomal doxorubicin 10iberdomide 10Prednisone 10venetoclax 9selinexor 9isatuximab 9Mycophenolic Acid 9pembrolizumab 8Cyclosporine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Multiple Myeloma × radium Ra 223 dichloride × Clear all
NCT02928029 2020-02-26

Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma

Bayer

Phase 1/2 Terminated
7 enrolled 9 charts
Plasma cell

Multiple Myeloma

NCT02605356 2016-10-07

Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma

Bayer

Phase 1/2 Withdrawn
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡